Date: Thursday 22nd June 2023
Time: 08:00-09:00 PDT | 11:00-12:00 ET | 16:00-17:00 BST | 17:00-18:00 CEST
Speakers: Dr. Heng Li (FDA), Dr. Lilly Yue (FDA) and Dr. Jason (Jixian) Wang (Bristol Myers Squibb). Chair: Amy Mulick (Veramed).
Who is this event intended for? Anyone interested in learning more about propensity scores.
What are the benefits of attending? People should attend to learn more about the different techniques and applications propensity scores and the advantages and disadvantages of different methods.
Overview
Please join us to hear Dr. Heng Li & Dr. Lilly Yue (FDA), and Dr. Jason (Jixian) Wang (Bristol Myers Squibb) present their recent work.
Presenters and Papers:
1. Heng Li, Lilly Q. Yue: Propensity score-based methods for causal inference and external data leveraging in regulatory settings: From basic ideas to implementation https://onlinelibrary.wiley.com/doi/10.1002/pst.2294
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
Registration
This event is free to attend for both Members of PSI and Non-Members.
To register, please click here.
Speaker details
Speaker
Biography
Dr. Heng Li
Dr. Heng Li is a Lead Mathematical Statistician in the Division of Biostatistics, CDRH/FDA. He is instrumental in the establishment and evaluation of policies and procedures to maintain a unified and consistent program for biostatistical aspects of the regulation of medical device. He leads a team of statisticians in technical reviews and research. He has made substantial contributions in advancing regulatory statistics, especially propensity score-based methods, including developing and implementing novel propensity score-based approaches for leveraging real-world evidence to support regulatory decision-making.
Dr. Lilly Yue
Dr. Lilly Yue is a Deputy Director, Division of Biostatistics in the FDA's Center for Devices and Radiological Health, where she oversees statistical reviews of therapeutic and diagnostic medical devices. She has played a key leadership role in advancing regulatory statistics, including efforts on adapting and advancing propensity score methodology for premarket observational studies and on developing and implementing the novel propensity score-integrated approaches for leveraging real-world evidence to support regulatory decision-making. Dr. Yue is an Editor-in-Chief of Pharmaceutical Statistics and served as an Associate Editor (and a Guest Editor) for Journal of Biopharmaceutical Statistics and Pharmaceutical Statistics. She is a Fellow of the American Statistical Association.
Dr. Jason (Jixian) Wang
Jason (Jixian) Wang is a statistician in Statistical Methodology Group in Bristol Myers Squibb based in Switzerland. He has more than 20 years’ experience in the pharmaceutical industry, has worked in several therapeutic areas such as cardiovascular, oncology, hematology, and cell therapies, and in difference phases including clinical development, in which he did multiple regulatory submissions, as well as pre-clinical statistics, clinical pharmacology, and post-marketing drug safety and HTA. He was an academic researcher in biostatistics and epidemiology before joining the industry. He has a wide range of research interests including casual inference, innovative trial designs, dose optimization, machine learning, and PK/PD and health economics modeling and simulation. He published more than 60 papers, one book and two book chapters. He is a member of the RWD SIG in PSI/EFSPI.
Chair
Chair
Biography
Amy Mulick
Amy is Head of the Evidence and Value Generation group at Veramed, which generates clinical evidence for pharmaceutical products and medical devices using data collected partially or wholly outside the context of randomised controlled trials. Previously she was based at the London School of Hygiene and Tropical Medicine using the Clinical Practice Research Datalink (CPRD) to research disease epidemiology, and developing a novel cause of death estimation method to cope with sparse data inputs. She has expertise in Bayesian methods for evidence synthesis as well as causal and predictive statistical modelling.
Date: Thursday 22nd June 2023
Time: 08:00-09:00 PDT | 11:00-12:00 ET | 16:00-17:00 BST | 17:00-18:00 CEST
Speakers: Dr. Heng Li (FDA), Dr. Lilly Yue (FDA) and Dr. Jason (Jixian) Wang (Bristol Myers Squibb). Chair: Amy Mulick (Veramed).
Who is this event intended for? Anyone interested in learning more about propensity scores.
What are the benefits of attending? People should attend to learn more about the different techniques and applications propensity scores and the advantages and disadvantages of different methods.
Overview
Please join us to hear Dr. Heng Li & Dr. Lilly Yue (FDA), and Dr. Jason (Jixian) Wang (Bristol Myers Squibb) present their recent work.
Presenters and Papers:
1. Heng Li, Lilly Q. Yue: Propensity score-based methods for causal inference and external data leveraging in regulatory settings: From basic ideas to implementation https://onlinelibrary.wiley.com/doi/10.1002/pst.2294
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
Registration
This event is free to attend for both Members of PSI and Non-Members.
To register, please click here.
Speaker details
Speaker
Biography
Dr. Heng Li
Dr. Heng Li is a Lead Mathematical Statistician in the Division of Biostatistics, CDRH/FDA. He is instrumental in the establishment and evaluation of policies and procedures to maintain a unified and consistent program for biostatistical aspects of the regulation of medical device. He leads a team of statisticians in technical reviews and research. He has made substantial contributions in advancing regulatory statistics, especially propensity score-based methods, including developing and implementing novel propensity score-based approaches for leveraging real-world evidence to support regulatory decision-making.
Dr. Lilly Yue
Dr. Lilly Yue is a Deputy Director, Division of Biostatistics in the FDA's Center for Devices and Radiological Health, where she oversees statistical reviews of therapeutic and diagnostic medical devices. She has played a key leadership role in advancing regulatory statistics, including efforts on adapting and advancing propensity score methodology for premarket observational studies and on developing and implementing the novel propensity score-integrated approaches for leveraging real-world evidence to support regulatory decision-making. Dr. Yue is an Editor-in-Chief of Pharmaceutical Statistics and served as an Associate Editor (and a Guest Editor) for Journal of Biopharmaceutical Statistics and Pharmaceutical Statistics. She is a Fellow of the American Statistical Association.
Dr. Jason (Jixian) Wang
Jason (Jixian) Wang is a statistician in Statistical Methodology Group in Bristol Myers Squibb based in Switzerland. He has more than 20 years’ experience in the pharmaceutical industry, has worked in several therapeutic areas such as cardiovascular, oncology, hematology, and cell therapies, and in difference phases including clinical development, in which he did multiple regulatory submissions, as well as pre-clinical statistics, clinical pharmacology, and post-marketing drug safety and HTA. He was an academic researcher in biostatistics and epidemiology before joining the industry. He has a wide range of research interests including casual inference, innovative trial designs, dose optimization, machine learning, and PK/PD and health economics modeling and simulation. He published more than 60 papers, one book and two book chapters. He is a member of the RWD SIG in PSI/EFSPI.
Chair
Chair
Biography
Amy Mulick
Amy is Head of the Evidence and Value Generation group at Veramed, which generates clinical evidence for pharmaceutical products and medical devices using data collected partially or wholly outside the context of randomised controlled trials. Previously she was based at the London School of Hygiene and Tropical Medicine using the Clinical Practice Research Datalink (CPRD) to research disease epidemiology, and developing a novel cause of death estimation method to cope with sparse data inputs. She has expertise in Bayesian methods for evidence synthesis as well as causal and predictive statistical modelling.
Date: Thursday 22nd June 2023
Time: 08:00-09:00 PDT | 11:00-12:00 ET | 16:00-17:00 BST | 17:00-18:00 CEST
Speakers: Dr. Heng Li (FDA), Dr. Lilly Yue (FDA) and Dr. Jason (Jixian) Wang (Bristol Myers Squibb). Chair: Amy Mulick (Veramed).
Who is this event intended for? Anyone interested in learning more about propensity scores.
What are the benefits of attending? People should attend to learn more about the different techniques and applications propensity scores and the advantages and disadvantages of different methods.
Overview
Please join us to hear Dr. Heng Li & Dr. Lilly Yue (FDA), and Dr. Jason (Jixian) Wang (Bristol Myers Squibb) present their recent work.
Presenters and Papers:
1. Heng Li, Lilly Q. Yue: Propensity score-based methods for causal inference and external data leveraging in regulatory settings: From basic ideas to implementation https://onlinelibrary.wiley.com/doi/10.1002/pst.2294
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
Registration
This event is free to attend for both Members of PSI and Non-Members.
To register, please click here.
Speaker details
Speaker
Biography
Dr. Heng Li
Dr. Heng Li is a Lead Mathematical Statistician in the Division of Biostatistics, CDRH/FDA. He is instrumental in the establishment and evaluation of policies and procedures to maintain a unified and consistent program for biostatistical aspects of the regulation of medical device. He leads a team of statisticians in technical reviews and research. He has made substantial contributions in advancing regulatory statistics, especially propensity score-based methods, including developing and implementing novel propensity score-based approaches for leveraging real-world evidence to support regulatory decision-making.
Dr. Lilly Yue
Dr. Lilly Yue is a Deputy Director, Division of Biostatistics in the FDA's Center for Devices and Radiological Health, where she oversees statistical reviews of therapeutic and diagnostic medical devices. She has played a key leadership role in advancing regulatory statistics, including efforts on adapting and advancing propensity score methodology for premarket observational studies and on developing and implementing the novel propensity score-integrated approaches for leveraging real-world evidence to support regulatory decision-making. Dr. Yue is an Editor-in-Chief of Pharmaceutical Statistics and served as an Associate Editor (and a Guest Editor) for Journal of Biopharmaceutical Statistics and Pharmaceutical Statistics. She is a Fellow of the American Statistical Association.
Dr. Jason (Jixian) Wang
Jason (Jixian) Wang is a statistician in Statistical Methodology Group in Bristol Myers Squibb based in Switzerland. He has more than 20 years’ experience in the pharmaceutical industry, has worked in several therapeutic areas such as cardiovascular, oncology, hematology, and cell therapies, and in difference phases including clinical development, in which he did multiple regulatory submissions, as well as pre-clinical statistics, clinical pharmacology, and post-marketing drug safety and HTA. He was an academic researcher in biostatistics and epidemiology before joining the industry. He has a wide range of research interests including casual inference, innovative trial designs, dose optimization, machine learning, and PK/PD and health economics modeling and simulation. He published more than 60 papers, one book and two book chapters. He is a member of the RWD SIG in PSI/EFSPI.
Chair
Chair
Biography
Amy Mulick
Amy is Head of the Evidence and Value Generation group at Veramed, which generates clinical evidence for pharmaceutical products and medical devices using data collected partially or wholly outside the context of randomised controlled trials. Previously she was based at the London School of Hygiene and Tropical Medicine using the Clinical Practice Research Datalink (CPRD) to research disease epidemiology, and developing a novel cause of death estimation method to cope with sparse data inputs. She has expertise in Bayesian methods for evidence synthesis as well as causal and predictive statistical modelling.
Date: Thursday 22nd June 2023
Time: 08:00-09:00 PDT | 11:00-12:00 ET | 16:00-17:00 BST | 17:00-18:00 CEST
Speakers: Dr. Heng Li (FDA), Dr. Lilly Yue (FDA) and Dr. Jason (Jixian) Wang (Bristol Myers Squibb). Chair: Amy Mulick (Veramed).
Who is this event intended for? Anyone interested in learning more about propensity scores.
What are the benefits of attending? People should attend to learn more about the different techniques and applications propensity scores and the advantages and disadvantages of different methods.
Overview
Please join us to hear Dr. Heng Li & Dr. Lilly Yue (FDA), and Dr. Jason (Jixian) Wang (Bristol Myers Squibb) present their recent work.
Presenters and Papers:
1. Heng Li, Lilly Q. Yue: Propensity score-based methods for causal inference and external data leveraging in regulatory settings: From basic ideas to implementation https://onlinelibrary.wiley.com/doi/10.1002/pst.2294
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
Registration
This event is free to attend for both Members of PSI and Non-Members.
To register, please click here.
Speaker details
Speaker
Biography
Dr. Heng Li
Dr. Heng Li is a Lead Mathematical Statistician in the Division of Biostatistics, CDRH/FDA. He is instrumental in the establishment and evaluation of policies and procedures to maintain a unified and consistent program for biostatistical aspects of the regulation of medical device. He leads a team of statisticians in technical reviews and research. He has made substantial contributions in advancing regulatory statistics, especially propensity score-based methods, including developing and implementing novel propensity score-based approaches for leveraging real-world evidence to support regulatory decision-making.
Dr. Lilly Yue
Dr. Lilly Yue is a Deputy Director, Division of Biostatistics in the FDA's Center for Devices and Radiological Health, where she oversees statistical reviews of therapeutic and diagnostic medical devices. She has played a key leadership role in advancing regulatory statistics, including efforts on adapting and advancing propensity score methodology for premarket observational studies and on developing and implementing the novel propensity score-integrated approaches for leveraging real-world evidence to support regulatory decision-making. Dr. Yue is an Editor-in-Chief of Pharmaceutical Statistics and served as an Associate Editor (and a Guest Editor) for Journal of Biopharmaceutical Statistics and Pharmaceutical Statistics. She is a Fellow of the American Statistical Association.
Dr. Jason (Jixian) Wang
Jason (Jixian) Wang is a statistician in Statistical Methodology Group in Bristol Myers Squibb based in Switzerland. He has more than 20 years’ experience in the pharmaceutical industry, has worked in several therapeutic areas such as cardiovascular, oncology, hematology, and cell therapies, and in difference phases including clinical development, in which he did multiple regulatory submissions, as well as pre-clinical statistics, clinical pharmacology, and post-marketing drug safety and HTA. He was an academic researcher in biostatistics and epidemiology before joining the industry. He has a wide range of research interests including casual inference, innovative trial designs, dose optimization, machine learning, and PK/PD and health economics modeling and simulation. He published more than 60 papers, one book and two book chapters. He is a member of the RWD SIG in PSI/EFSPI.
Chair
Chair
Biography
Amy Mulick
Amy is Head of the Evidence and Value Generation group at Veramed, which generates clinical evidence for pharmaceutical products and medical devices using data collected partially or wholly outside the context of randomised controlled trials. Previously she was based at the London School of Hygiene and Tropical Medicine using the Clinical Practice Research Datalink (CPRD) to research disease epidemiology, and developing a novel cause of death estimation method to cope with sparse data inputs. She has expertise in Bayesian methods for evidence synthesis as well as causal and predictive statistical modelling.
Date: Thursday 22nd June 2023
Time: 08:00-09:00 PDT | 11:00-12:00 ET | 16:00-17:00 BST | 17:00-18:00 CEST
Speakers: Dr. Heng Li (FDA), Dr. Lilly Yue (FDA) and Dr. Jason (Jixian) Wang (Bristol Myers Squibb). Chair: Amy Mulick (Veramed).
Who is this event intended for? Anyone interested in learning more about propensity scores.
What are the benefits of attending? People should attend to learn more about the different techniques and applications propensity scores and the advantages and disadvantages of different methods.
Overview
Please join us to hear Dr. Heng Li & Dr. Lilly Yue (FDA), and Dr. Jason (Jixian) Wang (Bristol Myers Squibb) present their recent work.
Presenters and Papers:
1. Heng Li, Lilly Q. Yue: Propensity score-based methods for causal inference and external data leveraging in regulatory settings: From basic ideas to implementation https://onlinelibrary.wiley.com/doi/10.1002/pst.2294
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
Registration
This event is free to attend for both Members of PSI and Non-Members.
To register, please click here.
Speaker details
Speaker
Biography
Dr. Heng Li
Dr. Heng Li is a Lead Mathematical Statistician in the Division of Biostatistics, CDRH/FDA. He is instrumental in the establishment and evaluation of policies and procedures to maintain a unified and consistent program for biostatistical aspects of the regulation of medical device. He leads a team of statisticians in technical reviews and research. He has made substantial contributions in advancing regulatory statistics, especially propensity score-based methods, including developing and implementing novel propensity score-based approaches for leveraging real-world evidence to support regulatory decision-making.
Dr. Lilly Yue
Dr. Lilly Yue is a Deputy Director, Division of Biostatistics in the FDA's Center for Devices and Radiological Health, where she oversees statistical reviews of therapeutic and diagnostic medical devices. She has played a key leadership role in advancing regulatory statistics, including efforts on adapting and advancing propensity score methodology for premarket observational studies and on developing and implementing the novel propensity score-integrated approaches for leveraging real-world evidence to support regulatory decision-making. Dr. Yue is an Editor-in-Chief of Pharmaceutical Statistics and served as an Associate Editor (and a Guest Editor) for Journal of Biopharmaceutical Statistics and Pharmaceutical Statistics. She is a Fellow of the American Statistical Association.
Dr. Jason (Jixian) Wang
Jason (Jixian) Wang is a statistician in Statistical Methodology Group in Bristol Myers Squibb based in Switzerland. He has more than 20 years’ experience in the pharmaceutical industry, has worked in several therapeutic areas such as cardiovascular, oncology, hematology, and cell therapies, and in difference phases including clinical development, in which he did multiple regulatory submissions, as well as pre-clinical statistics, clinical pharmacology, and post-marketing drug safety and HTA. He was an academic researcher in biostatistics and epidemiology before joining the industry. He has a wide range of research interests including casual inference, innovative trial designs, dose optimization, machine learning, and PK/PD and health economics modeling and simulation. He published more than 60 papers, one book and two book chapters. He is a member of the RWD SIG in PSI/EFSPI.
Chair
Chair
Biography
Amy Mulick
Amy is Head of the Evidence and Value Generation group at Veramed, which generates clinical evidence for pharmaceutical products and medical devices using data collected partially or wholly outside the context of randomised controlled trials. Previously she was based at the London School of Hygiene and Tropical Medicine using the Clinical Practice Research Datalink (CPRD) to research disease epidemiology, and developing a novel cause of death estimation method to cope with sparse data inputs. She has expertise in Bayesian methods for evidence synthesis as well as causal and predictive statistical modelling.
Date: Thursday 22nd June 2023
Time: 08:00-09:00 PDT | 11:00-12:00 ET | 16:00-17:00 BST | 17:00-18:00 CEST
Speakers: Dr. Heng Li (FDA), Dr. Lilly Yue (FDA) and Dr. Jason (Jixian) Wang (Bristol Myers Squibb). Chair: Amy Mulick (Veramed).
Who is this event intended for? Anyone interested in learning more about propensity scores.
What are the benefits of attending? People should attend to learn more about the different techniques and applications propensity scores and the advantages and disadvantages of different methods.
Overview
Please join us to hear Dr. Heng Li & Dr. Lilly Yue (FDA), and Dr. Jason (Jixian) Wang (Bristol Myers Squibb) present their recent work.
Presenters and Papers:
1. Heng Li, Lilly Q. Yue: Propensity score-based methods for causal inference and external data leveraging in regulatory settings: From basic ideas to implementation https://onlinelibrary.wiley.com/doi/10.1002/pst.2294
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
Registration
This event is free to attend for both Members of PSI and Non-Members.
To register, please click here.
Speaker details
Speaker
Biography
Dr. Heng Li
Dr. Heng Li is a Lead Mathematical Statistician in the Division of Biostatistics, CDRH/FDA. He is instrumental in the establishment and evaluation of policies and procedures to maintain a unified and consistent program for biostatistical aspects of the regulation of medical device. He leads a team of statisticians in technical reviews and research. He has made substantial contributions in advancing regulatory statistics, especially propensity score-based methods, including developing and implementing novel propensity score-based approaches for leveraging real-world evidence to support regulatory decision-making.
Dr. Lilly Yue
Dr. Lilly Yue is a Deputy Director, Division of Biostatistics in the FDA's Center for Devices and Radiological Health, where she oversees statistical reviews of therapeutic and diagnostic medical devices. She has played a key leadership role in advancing regulatory statistics, including efforts on adapting and advancing propensity score methodology for premarket observational studies and on developing and implementing the novel propensity score-integrated approaches for leveraging real-world evidence to support regulatory decision-making. Dr. Yue is an Editor-in-Chief of Pharmaceutical Statistics and served as an Associate Editor (and a Guest Editor) for Journal of Biopharmaceutical Statistics and Pharmaceutical Statistics. She is a Fellow of the American Statistical Association.
Dr. Jason (Jixian) Wang
Jason (Jixian) Wang is a statistician in Statistical Methodology Group in Bristol Myers Squibb based in Switzerland. He has more than 20 years’ experience in the pharmaceutical industry, has worked in several therapeutic areas such as cardiovascular, oncology, hematology, and cell therapies, and in difference phases including clinical development, in which he did multiple regulatory submissions, as well as pre-clinical statistics, clinical pharmacology, and post-marketing drug safety and HTA. He was an academic researcher in biostatistics and epidemiology before joining the industry. He has a wide range of research interests including casual inference, innovative trial designs, dose optimization, machine learning, and PK/PD and health economics modeling and simulation. He published more than 60 papers, one book and two book chapters. He is a member of the RWD SIG in PSI/EFSPI.
Chair
Chair
Biography
Amy Mulick
Amy is Head of the Evidence and Value Generation group at Veramed, which generates clinical evidence for pharmaceutical products and medical devices using data collected partially or wholly outside the context of randomised controlled trials. Previously she was based at the London School of Hygiene and Tropical Medicine using the Clinical Practice Research Datalink (CPRD) to research disease epidemiology, and developing a novel cause of death estimation method to cope with sparse data inputs. She has expertise in Bayesian methods for evidence synthesis as well as causal and predictive statistical modelling.
Upcoming Events
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
Joint PSI/EFSPI Data Science SIG Webinar: Developing Digital Measures (Digital Biomarkers) in Drug Development – insights from Mobilise D consortium
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Webinar: Development of Gene Therapies: Strategic, Scientific, Regulatory and Access Considerations
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK